Coenzyme Q10 Administration Significantly Reduces Systolic Blood Pressure1

A meta-analysis of 45 randomised controlled trials evaluated the efficacy of coenzyme Q10 administration on cardiovascular parameters in adults. The statistical synthesis demonstrated a significant reduction in systolic blood pressure, whereas changes in diastolic blood pressure and heart rate remained non-significant. Subgroup analyses showed greater systolic blood pressure reduction with doses under 200 mg daily or treatment durations exceeding 8 weeks. Patients with underlying health conditions also experienced greater therapeutic improvements compared to healthy individuals. Consequently, coenzyme Q10 serves as an effective, safe supportive therapy for managing systolic hypertension.

References

1. Karimi M, et al. Int J Cardiol Cardiovasc Risk Prev. 2025;26:200424. 2. Brandt T, et al. Front. Physiol. 2025;16:1519240. 3. Weilnhammer V, et al. Nat Med. 2026. https://doi.org/10.1038/s41591-026-04577-2. 4. World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group. Available from: https://www.ox.ac.uk/news/2026-07-13-worlds-first-phase-i-bundibugyo-ebolavirus-vaccine-trial-launched-by 5. Köstekçi H, et al. Physiother Res Int. 2026;31(1):e70144. 6. Fukagawa NK, et al. Am J Clin Nutr. 2026;124(2):101396.